NEW YORK (GenomeWeb) – Luminex announced today that it has raised the purchase price for Nanosphere to $1.70 per share in cash from the $1.35-per-share price it originally offered for the molecular diagnostics developer.

This raises the share-price value of the transaction to approximately $77 million from $58 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.